DarioHealth (DRIO) Stock Price, News & Analysis

Company Overview

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key Stats

• Today's Range: $8.56 to $11.13
• 50-Day Range: $8.57 to $14.40
• 52-Week Range: $7.60 to $31.00
• Volume: 47,530 shs
• Average Volume: 251,369 shs
• Market Capitalization: $463.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Moderate Buy

DarioHealth Stock Analysis - MarketRank™

DarioHealth scored higher than 29% of companies evaluated by MarketBeat, and ranked 839th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DarioHealth has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

DarioHealth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DarioHealth are expected to grow in the coming year, from ($1.18) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DarioHealth is -15.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DarioHealth is -15.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DarioHealth has a P/B Ratio of 7.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.52% of the float of DarioHealth has been sold short.

Short Interest Ratio / Days to Cover

DarioHealth has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DarioHealth has recently increased by 2.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DarioHealth does not currently pay a dividend.

Dividend Growth

DarioHealth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.52% of the float of DarioHealth has been sold short.

Short Interest Ratio / Days to Cover

DarioHealth has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DarioHealth has recently increased by 2.70%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.36

News Sentiment

DarioHealth has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for DarioHealth this week, compared to 1 article on an average week.

Search Interest

1 people have searched for DRIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DarioHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.20% of the stock of DarioHealth is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.39% of the stock of DarioHealth is held by institutions.

DRIO Stock Analysis - Frequently Asked Questions

How have DRIO shares performed this year?

DarioHealth's stock was trading at $15.7220 at the beginning of 2025. Since then, DRIO stock has decreased by 35.2% and is now trading at $10.18.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($2.80) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $1.40. The firm earned $6.75 million during the quarter, compared to analysts' expectations of $7.48 million. DarioHealth had a negative net margin of 162.73% and a negative trailing twelve-month return on equity of 65.89%.
Read the conference call transcript.

When did DarioHealth's stock split?

Shares of DarioHealth reverse split before market open on Thursday, August 28th 2025.The 1-20 reverse split was announced on Monday, August 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Does DarioHealth have any subsidiaries?

DarioHealth subsidiaries include these companies: PsyInnovations Inc., Upright Technologies Ltd., Labstyle Innovation Ltd., PsyInnovations India Private Limited., and Upright Technologies Inc..

Who are DarioHealth's major shareholders?

Top institutional shareholders of DarioHealth include AMH Equity Ltd (0.47%) and XTX Topco Ltd (0.14%). Insiders that own company stock include Erez Raphael and Steven Charles Nelson.
View institutional ownership trends.

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DarioHealth investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DRIO
• CIK: 1533998
• Web: www.mydario.com
• Phone: (833) 914-3796
• Fax: 972-4770-4059
• Employees: 200
• Year Founded: 2011

Price Target and Rating

• Average Price Target for DarioHealth: $40.00
• High Price Target: $60.00
• Low Price Target: $20.00
• Potential Upside/Downside: +292.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.75 million
• Net Margins: -162.73%
• Pretax Margin: -162.13%
• Return on Equity: -65.89%
• Return on Assets: -39.03%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 3.30
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: $27.04 million
• Price / Sales: 17.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 7.22

Miscellaneous

• Outstanding Shares: 45,500,000
• Free Float: 40,401,000
• Market Cap: $463.19 million
• Optionable: Optionable
• Beta: 1.24